ciprofloxacin has been researched along with Febrile Neutropenia in 12 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Febrile Neutropenia: Fever accompanied by a significant reduction in the number of NEUTROPHILS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A phase III randomized, controlled, clinical trial, open-label parallel-group with a 1:1 ratio, aimed to demonstrate the non-inferiority of oral fosfomycin versus oral ciprofloxacin for febrile neutropenia prevention in patients with acute leukemia (AL) or hematopoietic cell transplant (HSC) receptors." | 9.69 | FOVOCIP study: a multicenter randomized trial of fosfomycin versus ciprofloxacin for febrile neutropenia in hematologic patients-efficacy and microbiologic safety. ( Amigo, ML; Bernal, T; Blanco, LS; Boluda, B; Burgués, JMB; Calabuig, ML; Casas, MC; de Miguel, MI; de Ugarriza, PL; Del Mar García-Saiz, M; Domínguez, JF; Hernández, SC; Huerta, AJG; Humala, K; Lavín-Alconero, L; Moreno, AF; Verdugo, AF; Zarzuela, MP, 2023) |
| "Early-stage breast cancer patients receiving TC chemotherapy were randomised to either ciprofloxacin or G-CSF." | 9.30 | Feasibility of using a pragmatic trials model to compare two primary febrile neutropenia prophylaxis regimens (ciprofloxacin versus G-CSF) in patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer (REaCT-TC). ( Clemons, M; Fergusson, D; Hilton, J; Hutton, B; Ibrahim, MF; Joy, A; Kehoe, A; Mallick, R; Mazzarello, S; Price-Hiller, J; Sienkiewicz, M; Stober, C; Vandermeer, L; Verma, S; Zhu, X, 2019) |
| "The purpose of this study was to identify risk factors and improve preventive strategies for febrile neutropenia (FEN) in children with leukemia who were receiving ciprofloxacin prophylaxis." | 8.31 | Identifying Risk Factors and Improving Preventive Strategies for Febrile Neutropenia in Children with Leukemia Receiving Ciprofloxacin Prophylaxis ( Alıcı, N; Kaya, Z; Kırkız, S; Koçak, Ü, 2023) |
| " We compared the incidence of bacterial-related complications among 356 patients with multiple myeloma (MM) (n = 202) and lymphoma (n = 154) who underwent AHCT with (n = 177) or without (n = 179) ciprofloxacin prophylaxis between 03/2007 and 10/2012 and between 10/2012 and 07/2016, respectively, at a single centre." | 7.88 | Antibacterial prophylaxis with ciprofloxacin for patients with multiple myeloma and lymphoma undergoing autologous haematopoietic cell transplantation: a quasi-experimental single-centre before-after study. ( Bishara, J; Gurion, R; Herscovici, C; Lahav, M; Magen, H; Moshe, M; Naparstek, E; Pasvolsky, O; Peck, A; Raanani, P; Rozovski, U; Sela-Navon, M; Shargian, L; Vaxman, I; Vidal, L; Wolach, O; Yahav, D; Yeshurun, M, 2018) |
| "A phase III randomized, controlled, clinical trial, open-label parallel-group with a 1:1 ratio, aimed to demonstrate the non-inferiority of oral fosfomycin versus oral ciprofloxacin for febrile neutropenia prevention in patients with acute leukemia (AL) or hematopoietic cell transplant (HSC) receptors." | 5.69 | FOVOCIP study: a multicenter randomized trial of fosfomycin versus ciprofloxacin for febrile neutropenia in hematologic patients-efficacy and microbiologic safety. ( Amigo, ML; Bernal, T; Blanco, LS; Boluda, B; Burgués, JMB; Calabuig, ML; Casas, MC; de Miguel, MI; de Ugarriza, PL; Del Mar García-Saiz, M; Domínguez, JF; Hernández, SC; Huerta, AJG; Humala, K; Lavín-Alconero, L; Moreno, AF; Verdugo, AF; Zarzuela, MP, 2023) |
| "Early-stage breast cancer patients receiving TC chemotherapy were randomised to either ciprofloxacin or G-CSF." | 5.30 | Feasibility of using a pragmatic trials model to compare two primary febrile neutropenia prophylaxis regimens (ciprofloxacin versus G-CSF) in patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer (REaCT-TC). ( Clemons, M; Fergusson, D; Hilton, J; Hutton, B; Ibrahim, MF; Joy, A; Kehoe, A; Mallick, R; Mazzarello, S; Price-Hiller, J; Sienkiewicz, M; Stober, C; Vandermeer, L; Verma, S; Zhu, X, 2019) |
| "The purpose of this study was to identify risk factors and improve preventive strategies for febrile neutropenia (FEN) in children with leukemia who were receiving ciprofloxacin prophylaxis." | 4.31 | Identifying Risk Factors and Improving Preventive Strategies for Febrile Neutropenia in Children with Leukemia Receiving Ciprofloxacin Prophylaxis ( Alıcı, N; Kaya, Z; Kırkız, S; Koçak, Ü, 2023) |
| " We compared the incidence of bacterial-related complications among 356 patients with multiple myeloma (MM) (n = 202) and lymphoma (n = 154) who underwent AHCT with (n = 177) or without (n = 179) ciprofloxacin prophylaxis between 03/2007 and 10/2012 and between 10/2012 and 07/2016, respectively, at a single centre." | 3.88 | Antibacterial prophylaxis with ciprofloxacin for patients with multiple myeloma and lymphoma undergoing autologous haematopoietic cell transplantation: a quasi-experimental single-centre before-after study. ( Bishara, J; Gurion, R; Herscovici, C; Lahav, M; Magen, H; Moshe, M; Naparstek, E; Pasvolsky, O; Peck, A; Raanani, P; Rozovski, U; Sela-Navon, M; Shargian, L; Vaxman, I; Vidal, L; Wolach, O; Yahav, D; Yeshurun, M, 2018) |
| "Febrile neutropenia: is ambulatory care possible ? Outpatient treatment of neutropenic fever post chemotherapy is possible for patients at low risk of complications." | 1.46 | [Febrile neutropenia: is ambulatory care possible]? ( Lafaurie, M, 2017) |
| "One patient developed Fusarium infection." | 1.40 | Bloodstream and central line isolates from hematopoietic stem cell transplant recipients: data from a developing country. ( Adil, SN; Ali, N; Shaikh, MU, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 4 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Yeh, TC | 1 |
| Hou, JY | 1 |
| Huang, TH | 1 |
| Lu, CH | 1 |
| Sun, FJ | 1 |
| Huang, HM | 1 |
| Liu, HC | 1 |
| Kaya, Z | 1 |
| Alıcı, N | 1 |
| Kırkız, S | 1 |
| Koçak, Ü | 1 |
| Moreno, AF | 1 |
| Lavín-Alconero, L | 1 |
| de Ugarriza, PL | 1 |
| Blanco, LS | 1 |
| Hernández, SC | 1 |
| Burgués, JMB | 1 |
| de Miguel, MI | 1 |
| Huerta, AJG | 1 |
| Zarzuela, MP | 1 |
| Boluda, B | 1 |
| Humala, K | 1 |
| Calabuig, ML | 1 |
| Amigo, ML | 1 |
| Casas, MC | 1 |
| Del Mar García-Saiz, M | 1 |
| Verdugo, AF | 1 |
| Domínguez, JF | 1 |
| Bernal, T | 1 |
| Oliver, AC | 1 |
| Riva, E | 1 |
| Mosquera, R | 1 |
| Galeano, S | 1 |
| Pierri, S | 1 |
| Bello, L | 1 |
| Caneiro, A | 1 |
| Gai, R | 1 |
| Miller, A | 1 |
| Muxi, P | 1 |
| Conn, JR | 1 |
| Catchpoole, EM | 1 |
| Runnegar, N | 1 |
| Mapp, SJ | 1 |
| Markey, KA | 1 |
| Goodlet, KJ | 1 |
| Nicolau, DP | 1 |
| Nailor, MD | 1 |
| Yeshurun, M | 1 |
| Vaxman, I | 1 |
| Shargian, L | 1 |
| Yahav, D | 1 |
| Bishara, J | 1 |
| Pasvolsky, O | 1 |
| Wolach, O | 1 |
| Lahav, M | 1 |
| Gurion, R | 1 |
| Magen, H | 1 |
| Vidal, L | 1 |
| Herscovici, C | 1 |
| Peck, A | 1 |
| Moshe, M | 1 |
| Sela-Navon, M | 1 |
| Naparstek, E | 1 |
| Raanani, P | 1 |
| Rozovski, U | 1 |
| Clemons, M | 1 |
| Mazzarello, S | 1 |
| Hilton, J | 1 |
| Joy, A | 1 |
| Price-Hiller, J | 1 |
| Zhu, X | 1 |
| Verma, S | 1 |
| Kehoe, A | 1 |
| Ibrahim, MF | 1 |
| Sienkiewicz, M | 1 |
| Stober, C | 1 |
| Vandermeer, L | 1 |
| Hutton, B | 1 |
| Mallick, R | 1 |
| Fergusson, D | 1 |
| Lafaurie, M | 1 |
| Ali, N | 1 |
| Adil, SN | 1 |
| Shaikh, MU | 1 |
| Borget, I | 1 |
| Antoun, S | 1 |
| Chachaty, E | 1 |
| Gachot, B | 1 |
| Alibay, A | 1 |
| Di Palma, M | 1 |
| Merad, M | 1 |
| Hallböök, H | 1 |
| Lidström, AK | 1 |
| Pauksens, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Feasibility of Using an Integrated Consent Model to Compare Two Standard of Care Regimens for Primary Prophylaxis of Taxotere/Cyclophosphamide-Induces Febrile Neutropenia[NCT02173262] | Phase 4 | 142 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for ciprofloxacin and Febrile Neutropenia
9 other studies available for ciprofloxacin and Febrile Neutropenia
| Article | Year |
|---|---|
Effectiveness and antimicrobial susceptibility profiles during primary antimicrobial prophylaxis for pediatric acute myeloid leukemia.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Antifungal Agents; Bacteremia; Child; Ciprofloxacin; | 2021 |
Identifying Risk Factors and Improving Preventive Strategies for Febrile Neutropenia in Children with Leukemia Receiving Ciprofloxacin Prophylaxis
Topics: Child; Ciprofloxacin; Febrile Neutropenia; Humans; Leukemia, Myeloid, Acute; Precursor Cell Lymphobl | 2023 |
Comparison of two different anti-infectious approaches after high-dose chemotherapy and autologous stem cell transplantation for hematologic malignancies in a 12-year period in British Hospital, Uruguay.
Topics: Adolescent; Adult; Aged; Amikacin; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Prot | 2020 |
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Drug Combinations; Drug | 2017 |
Antibacterial prophylaxis with ciprofloxacin for patients with multiple myeloma and lymphoma undergoing autologous haematopoietic cell transplantation: a quasi-experimental single-centre before-after study.
Topics: Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteremia; Ciprofloxacin; Controlled Be | 2018 |
[Febrile neutropenia: is ambulatory care possible]?
Topics: Administration, Oral; Ambulatory Care; Anti-Bacterial Agents; Ciprofloxacin; Febrile Neutropenia; Hu | 2017 |
Bloodstream and central line isolates from hematopoietic stem cell transplant recipients: data from a developing country.
Topics: Acyclovir; Adolescent; Adult; Anti-Infective Agents; Bacteremia; Candida albicans; Candidiasis; Cath | 2014 |
[Modalities of management of cancer patients with febrile neutropenia in the oncology emergency unit of Gustave-Roussy and their related costs].
Topics: Adult; Aged; Ambulatory Care; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; | 2014 |
Ciprofloxacin prophylaxis delays initiation of broad-spectrum antibiotic therapy and reduces the overall use of antimicrobial agents during induction therapy for acute leukaemia: A single-centre study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Bacterial Infections; Carbapenems | 2016 |